Limited-stage small-cell lung cancer: Therapeutic options

ONCOLOGY

Volumn 21, Issue 3, 2007, Pages 303-312

  Ganti, Apar Kishor ^a,b   Zhen, Whining ^a   Kessinger, Anne ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; ANTINEOPLASTIC AGENT; BEC 2; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IDIOTYPIC ANTIBODY; IFOSFAMIDE; IRINOTECAN; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; OBLIMERSEN; PACLITAXEL; PLACEBO; PLATINUM DERIVATIVE; PODOPHYLLOTOXIN; PROTEIN BCL 2; SORAFENIB; SUNITINIB; TENIPOSIDE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VATALANIB; VINCRISTINE;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW TOXICITY; BRAIN METASTASIS; BRAIN RADIATION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG SUBSTITUTION; GERIATRIC PATIENT; HUMAN; LOW DRUG DOSE; LUNG CANCER; LUNG SMALL CELL CANCER; LYMPH NODE METASTASIS; META ANALYSIS; MULTIMODALITY CANCER THERAPY; PLEURA EFFUSION; PROGNOSIS; RADIATION DOSE FRACTIONATION; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

CARCINOMA, SMALL CELL; HUMANS; LUNG NEOPLASMS;

EID: 33947606783     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56:106-130, 2006.
2. Adjei AA, Marks RS, Bonner JA: Current guidelines for the management of small cell lung cancer. Mayo Clin Proc 74:809-816, 1999.
3. Travis WD: Pathology of lung cancer. Clin Chest Med 23:65-81, viii, 2002.
4. Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 111:1710-1717, 1997.
5. Mountain CF: A new international staging system for lung cancer. Chest 89:225S-233S, 1986.
6. Micke P, Faldum A, Metz T, et al: Staging small cell lung cancer: Veterans Administration Lung Study Group vs International Association for the Study of Lung Cancer-what limits limited disease? Lung Cancer 37:271-276, 2002.
7. Argiris A, Murren JR: Staging and clinical prognostic factors for small-cell lung cancer. Cancer J 7:437-447, 2001.
8. Dearing MP, Steinberg SM, Phelps R, et al: Outcome of patients with small-cell lung cancer: Effect of changes in staging procedures and imaging technology on prognostic factors over 14 years. J Clin Oncol 8:1042-1049, 1990.
9. Perry MC, Eaton WL, Propert KJ, et al: Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 316:912-918, 1987.
10. Work E, Nielsen OS, Bentzen SM, et al: Randomized study of initial vs late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group. J Clin Oncol 15:3030-3037, 1997.
11. Bunn PA Jr, Lichter AS, Makuch RW, et al: Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer. A prospective, randomized trial. Ann Intern Med 106:655-662, 1987.
12. Livingston RB, McCracken JD, Trauth CJ, et al: Isolated pleural effusion in small cell lung carcinoma: Favorable prognosis. A review of the Southwest Oncology Group experience. Chest 81:208-211, 1982.
13. Spiegelman D, Maurer LH, Ware JH, et al: Prognostic factors in small-cell carcinoma of the lung: An analysis of 1,521 patients. J Clin Oncol 7:344-354, 1989.
14. Urban T, Chastang C, Vaylet F, et al: Prognostic significance of supraclavicular lymph nodes in small cell lung cancer: A study from four consecutive clinical trials, including 1,370 patients. "Petites Cellules" Group. Chest 114:1538-1541, 1998.
15. Bonner JA, Sloan JA, Shanahan TG, et al: Phase III comparison of twice-daily split-course irradiation vs once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol 17:2681-2691, 1999.
16. Turrisi AT 3rd, Kim K, Blum R, et al: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265-271, 1999.
17. Shepherd FA, Ginsberg RJ, Haddad R, et al: Importance of clinical staging in limited small-cell lung cancer: A valuable system to separate prognostic subgroups. The University of Toronto Lung Oncology Group. J Clin Oncol 11:1592-1597, 1993.
18. Hinson JA Jr, Perry MC: Small cell lung cancer. CA Cancer J Clin 43:216-225, 1993.
19. Paesmans M, Sculier JP, Lecomte J, et al: Prognostic factors for patients with small cell lung carcinoma: Analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer 89:523-533, 2000.
20. Lassen U, Osterlind K, Hansen M, et al: Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years-an analysis of 1,714 consecutive patients. J Clin Oncol 13:1215-1220, 1995.
21. Byhardt RW, Hartz A, Libnoch JA, et al: Prognostic influence of TNM staging and LDH levels in small cell carcinoma of the lung (SCCL). Int J Radiat Oncol Biol Phys 12:771-777, 1986.
22. Albain KS, Crowley JJ, Livingston RB: Long-term survival and toxicity in small cell lung cancer. Expanded Southwest Oncology Group experience. Chest 99:1425-1432, 1991.
23. Rawson NS, Peto J: An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer 61:597-604, 1990.
24. Bremnes RM, Sundstrom S, Aasebo U, et al: The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer 39:303-313, 2003.
25. Morstyn G, Ihde DC, Lichter AS, et al: Small cell lung cancer 1973-1983: Early progress and recent obstacles. Int J Radiat Oncol Biol Phys 10:515-539, 1984.
26. Livingston RB, Moore TN, Heilbrun L, et al: Small-cell carcinoma of the lung: combined chemotherapy and radiation: A Southwest Oncology Group study. Ann Intern Med 88:194-199, 1978.
27. Feld R, Evans WK, DeBoer G, et al: Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung. J Clin Oncol 2:294-304, 1984.
28. Feld R, Pringle JF, Evans WK, et al: Combined modality treatment of small cell carcinoma of the lung. Arch Intern Med 141:469-473, 1981.
29. Sierocki JS, Hilaris BS, Hopfan S, et al: cis- Dichlorodiammineplatinum(II) and VP-16-213: An active induction regimen for small cell carcinoma of the lung. Cancer Treat Rep 63:1593-1597, 1979.
30. Evans WK, Shepherd FA, Feld R, et al: VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 3:1471-1477, 1985.
31. Sundstrom S, Bremnes RM, Kaasa S, et al: Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: Results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 20:4665-4672, 2002.
32. Feld R, Evans WK, Coy P, et al: Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Oncol 5:1401-1409, 1987.
33. Fukuoka M, Furuse K, Saijo N, et al: Randomized trial of cyclophosphamide, doxorubicin, and vincristine vs cisplatin and etoposide vs alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83:855-861, 1991.
34. Roth BJ, Johnson DH, Einhorn LH, et al: Randomized study of cyclophosphamide, doxorubicin, and vincristine vs etoposide and cisplatin vs alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10:282-291, 1992.
35. Pujol JL, Carestia L, Daures JP: Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen vs a regimen without this alkylating agent. Br J Cancer 83:8-15, 2000.
36. Skarlos DV, Samantas E, Kosmidis P, et al: Randomized comparison of etoposide-cisplatin vs etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Cooperative Oncology Group study. Ann Oncol 5:601-607, 1994.
37. Spigel DR, Hainsworth JD, Burris HA, et al: Long-term follow-up of limited stage small cell lung cancer patients treated with carboplatin-based chemotherapy and radiotherapy by the Minnie Pearl Cancer Research Network (MPCRN) (abstract 7222). Proc Am Soc Clin Oncol 23:668, 2004.
38. Artel-Cortes A, Gomez-Codina J, Gonzalez-Larriba JL, et al: Prospective randomized phase III trial of etoposide/cisplatin vs high-dose epirubicin/cisplatin in small-cell lung cancer. Clin Lung Cancer 6:175-183, 2004.
39. James LE, Rudd R, Gower NH, et al: A phase III randomised comparison of gemcitabine/carboplatin (GC) with cisplatin/ etoposide (PE) in patients with poor prognosis small cell lung cancer (SCLC) (abstract 1170). Proc Am Soc Clin Oncol 21:293a, 2002.
40. Ettinger DS, Berkey BA, Abrams RA, et ai: Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: A Radiation Therapy Oncology Group 9609 phase II study. J Clin Oncol 23:4991-4998, 2005.
41. Reck M, Jagos U, Grunwald F, et al: Long-term survival in SCLC after treatment with paclitaxel, carboplatin and etoposide-a phase II study. Lung Cancer 39:63-69, 2003.
42. Bremnes RM, Sundstrom S, Vilsvik J, et al: Multicenter phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung cancer. J Clin Oncol 19:3532-3538, 2001.
43. Reck M, von Pawel J, Macha HN, et al: Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: Quality of life and 6-years'-follow-up results from a randomised phase III trial. Lung Cancer 53:67-75, 2006.
44. Reck M, von Pawel J, Macha HN, et al: Randomized phase III trial of paclitaxel, etoposide, and carboplatin vs carboplatin, etoposide, and vincristine in patients with small-cell lung cancer. J Natl Cancer Inst 95:1118-1127, 2003.
45. Frei E 3rd, Canellos GP: Dose: A critical factor in cancer chemotherapy. Am J Med 69:585-594, 1980.
46. Pedrazzoli P, Ledermann JA, Lotz JP, et al: High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. Ann Oncol 17:1479-1488, 2006.
47. Humblet Y, Symann M, Bosly A, et al: Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J Clin Oncol 5:1864-1873, 1987.
48. Perey L, Benhattar J, Peters R, et al: High tumour contamination of leukaphereses in patients with small cell carcinoma of the lung: A comparison of immunocytochemistry and RT-PCR. Br J Cancer 85:1713-1721, 2001.
49. Gaspar LE, Gay EG, Crawford J, et al: Limited-stage small-cell lung cancer (stages I-III): Observations from the National Cancer Data Base. Clin Lung Cancer 6:355-360, 2005.
50. Schild SE, Stella PJ, Brooks BJ, et al: Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly. Cancer 103:2349-2354, 2005.
51. Schiller JH, Adak S, Cella D, et al: Topotecan vs observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593-a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 19:2114-2122, 2001.
52. Hanna NH, Sandier AB, Loehrer PJ Sr, et al: Maintenance daily oral etoposide vs no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: A Hoosier Oncology Group randomized study. Ann Oncol 13:95-102, 2002.
53. Johnson BE, Crawford J, Downey RJ, et al: Small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 4:602-622, 2006.
54. Rosti G, Bevilacqua G, Bidoli P, et al: Small cell lung cancer. Ann Oncol 17(suppl 2):ii5-10, 2006.
55. Johnson DH, Bass D, Einhorn LH, et al: Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: A randomized trial of the Southeastern Cancer Study Group. J Clin Oncol 11:1223-1229, 1993.
56. Osterlind K, Hansen HH, Hansen M, et al: Mortality and morbidity in long-term surviving patients treated with chemotherapy with or without irradiation for small-cell lung cancer. J Clin Oncol 4:1044-1052, 1986.
57. Pignon JP, Arriagada R, Ihde DC, et al: A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327:1618-1624, 1992.
58. Warde P, Payne D: Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10:890-895, 1992.
59. Laskin JJ, Erridge SC, Coldman AJ, et al: Population-based outcomes for small cell lung cancer: impact of standard management policies in British Columbia. Lung Cancer 43:7-16, 2004.
60. Coy P, Hudson I, Payne DG, et al: The effect of dose of thoracic irradiation on recurrence in patients with limited stage small cell lung cancer. Initial results of a Canadian Multicenter Randomized Trial. Int J Radiat Oncol Biol Phys 14:219-226, 1988.
61. Arriagada R, le Chevalier T, Ruffie P, et al: Alternating radiotherapy and chemotherapy in 173 consecutive patients with limited small cell lung carcinoma. GROP and the French Cancer Center's Lung Group. Int J Radiat Oncol Biol Phys 19:1135-1138, 1990.
62. Choi NC, Herndon J, Rosenman J, et al: Long term survival data from CALGB 8837: Radiation dose escalation and concurrent chemotherapy (CT) in limited stage small cell lung cancer (LD-SCLC). Possible radiation dose-survival relationship (abstract 1190). Proc Am Soc Clin Oncol 21:298a, 2002.
63. Perry MC, Herndon JE 3rd, Eaton WL, et al: Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: An update of Cancer and Leukemia Group B Study 8083. J Clin Oncol 16:2466-2467, 1998.
64. Jeremic B, Shibamoto Y, Acimovic L, et al: Initial vs delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: A randomized study. J Clin Oncol 15:893-900, 1997.
65. Skarlos DV, Samantas E, Briassoulis E, et al: Randomized comparison of early vs late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: A randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol 12:1231-1238, 2001.
66. Takada M, Fukuoka M, Kawahara M, et al: Phase III study of concurrent vs sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: Results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 20:3054-3060, 2002.
67. Murray N, Coy P, Pater JL, et al: Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 11:336-344, 1993.
68. De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J, et al: Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol 17:543-552, 2006.
69. James LE, Spiro S, O'Donnell KM: A randomised study of timing of thoracic irradiation in small cell lung cancer (SCLC)-Study 8. Lung Cancer 41(suppl):S23, 2003.
70. Fox W, Scadding JG: Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up. Lancet 2:63-65, 1973.
71. Martini N, Wittes RE, Hilaris BS, et al: Oat cell carcinoma of the lung. Clin Bull 5:144-148, 1975.
72. Mountain CF: Clinical biology of small cell carcinoma: Relationship to surgical therapy. Semin Oncol 5:272-279, 1978.
73. Kreisman H, Wolkove N, Quoix E: Small cell lung cancer presenting as a solitary pulmonary nodule. Chest 101:225-231, 1992.
74. Inoue M, Miyoshi S, Yasumitsu T, et al: Surgical results for small cell lung cancer based on the new TNM staging system. Thoracic Surgery Study Group of Osaka University, Osaka, Japan. Ann Thorac Surg 70:1615-1619, 2000.
75. de Antonio DG, Alfageme F, Gamez P, et al: Results of surgery in small cell carcinoma of the lung. Lung Cancer 52:299-304, 2006.
76. Lad T, Piantadosi S, Thomas P, et al: A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 106:320S-323S, 1994.
77. Hochstenbag MM, Twijnstra A, Wilmink JT, et al: Asymptomatic brain metastases (BM) in small cell lung cancer (SCLC): MR-imaging is useful at initial diagnosis. J Neurooncol 48:243-248, 2000.
78. Arriagada R, Le Chevalier T, Bone F, et al: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 87:183-190, 1995.
79. Ball DL, Matthews JP: Prophylactic cranial irradiation: More questions than answers. Semin Radiat Oncol 5:61-68, 1995.
80. Felletti R, Souhami RL, Spiro SG, et al: Social consequences of brain or liver relapse in small cell carcinoma of the bronchus. Radiother Oncol 4:335-339, 1985.
81. Hansen HH: Should initial treatment of small cell carcinoma include systemic chemoterapy and brain irradiation? Cancer Chemother Rep 3 4:239-241, 1973.
82. Le Pechoux C, Arriagada R: Prophylactic cranial irradiation in small cell lung cancer. Hematol Oncol Clin North Am 18:355-372, 2004.
83. Meert AP, Paesmans M, Berghmans T, et al: Prophylactic cranial irradiation in small cell lung cancer: A systematic review of the iterature with meta-analysis. BMC Cancer 1:5, 2001.
84. Auperin A, Arriagada R, Pignon JP, et al: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341:476-484, 1999.
85. Wolfson AH, Bains Y, Lu J, et al: Twice-daily prophylactic cranial irradiation for patients with limited disease small-cell lung cancer with complete response to chemotherapy and consolidative radiotherapy: Report of a single institutional phase II trial. Am J Clin Oncol 24:290-295, 2001.
86. Tai TH, Yu E, Dickof P, et al: Prophylactic cranial irradiation revisited: Cost-effectiveness and quality of life in small-cell lung cancer. Int J Radiat Oncol Biol Phys 52:68-74, 2002.
87. Lee JJ, Bekele BN, Zhou X, et al: Decision analysis for prophylactic cranial irradiation for patients with small-cell lung cancer. J Clin Oncol 24:3597-3603, 2006.
88. Potti A, Moazzam N, Ramar K, et al: CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma. Ann Oncol 14:894-897, 2003.
89. Potti A, Ganti AK, Tuchman SA, et al: HER-2/neu and CD117 (c-kit) overexpression in patients with pesticide exposure and extensive stage small cell lung carcinoma (ESSCLC). J Carcinog 4:8, 2005.
90. Dy GK, Miller AA, Mandrekar SJ, et al: A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: A CALGB and NCCTG study. Ann Oncol 16:1811-1816, 2005.
91. Heinrich MC, Blanke CD, Druker BJ, et al: Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20:1692-1703, 2002.
92. Tudor G, Aguilera A, Halverson DO, et al: Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-xL protein levels. Cell Death Differ 7:574-586, 2000.
93. Ziegler A, Luedke GH, Fabbro D, et al: Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Nati Cancer Inst 89:1027-1036, 1997.
94. Ikegaki N, Katsumata M, Minna J, et al: Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res 54:6-8, 1994.
95. Rudin CM, Otterson GA, Mauer AM, et al: A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol 13:539-545, 2002.
96. Stetler-Stevenson WO, Aznavoorian S, Liotta LA: Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9:541-573, 1993.
97. Shepherd FA, Giaccone G, Seymour L, et al: Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 20:4434-4439, 2002.
98. Grant SC, Kris MG, Houghton AN, et al: Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus bacillus Calmette-Guerin. Clin Cancer Res 5:1319-1323, 1999.
99. Giaccone G, Debruyne C, Felip E, et al: Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol 23:6854-6864, 2005.
100. Bodner SM, Minna JD, Jensen SM, et al: Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 7:743-749, 1992.
101. D'Amico D, Carbone D, Mitsudomi T, et al: High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene 7:339-346, 1992.
102. Antonia SJ, Mirza N, Fricke I, et al: Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 12:878-887, 2006.
103. Thomas A, Morgan B, Drevs J, et al: Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Semin Oncol 30:32-38, 2003.
104. Herbst RS, Onn A, Sandler A: Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 23:3243-3256, 2005.